Bioluminescence Ventures
Venture capitalSan Francisco · 1 people tracked
Find your way into Bioluminescence Ventures
1 people in our graph share verified history with the Bioluminescence Ventures team — schools, employers, funds. One of them is your warm intro.
Fund manager profile
Bioluminescence Ventures is a venture fund manager based in San Francisco. SEC filings show 2 venture funds on record, most recently Bioluminescence Ventures Fund II, L.P. ($127.1M offering) filed September 2023.
Source: SEC EDGAR Form D filings. Firm website data not yet available.
Team · 1 people
from public directoriesWhat they invest in
from 3 of 6 portfolio companiesBiotech ×2Healthtech ×2Medical Devices ×2AI & Machine Learning ×1Cybersecurity ×1Data & Infrastructure ×1Enterprise Software ×1
HQs:United States×6
Investments · 6 tracked
founders shown can be your intro pathBy year:2023 · 42022 · 12021 · 16 dated
Ensoma is a genomic medicine company developing a platform for in vivo engineering of hematopoietic stem cells (HSCs), combining an off-the-shelf delivery system with a gene engineering toolkit intended to treat diseases with a one-time treatment.
BiotechHealthtechMedical DevicesBoston, US
Albert Seymour(Director)
BoardKush Parmar(Executive Officer, Director)inPaula Soteropoulos(Director)Stephen Knight(Director)in
Board seatKouki Harasaki· per SEC Form D
Co-investors5AM VenturesAju IB Invesment CorporationCatalio Capital Management, LPDelos CapitalF-Prime CapitalSolasta Ventures+7 more
Karlsgate provides a data governance and identity protection platform (the Karlsgate Identity Exchange) that lets organizations match, share, and collaborate on sensitive data across partners and AI workflows without transmitting raw identifiers, using locally generated cryptonyms and single-use protected values.
CybersecurityData & InfrastructureEnterprise SoftwareBudd Lake, US
Brian Mulllin(Executive Officer, Director)Xian Zhou(Executive Officer, Director)Kouki Harasaki(Director)
Board seatKouki Harasaki· per SEC Form D · $5M raise · filed Mar 2022
Co-investorsMotley Fool Ventures
ReCode develops mRNA and gene correction therapeutics for genetic diseases, using proprietary lipid nanoparticle technology to deliver treatments to specific organs.
AI & Machine LearningBiotechHealthtechMedical DevicesMenlo Park, US
Dr. Daniel J. SiegwartArthur E Johnson(Executive Officer, Director)
Board seatKouki Harasaki· per SEC Form D · $290M raise · filed Sep 2023
Co-investorsAju IB Invesment CorporationEcoR1 CapitalEvolution VC PartnersMPM BioImpactOrbiMedOUP (Osage University Partners)+6 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Artificial, Inc.SURGE Therapeutics, Inc.Nido Biosciences
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Portfolio news
latest coverage across their companies
Ensoma · fiercebiotech.com · Aug 7, 2026
ReCode Therapeutics · geekwire.com · Jul 13, 2026
Frequently asked questions
- How many investments has Bioluminescence Ventures made?
- Bioluminescence Ventures has 6 tracked investments.
- Where is Bioluminescence Ventures located?
- Bioluminescence Ventures is headquartered in San Francisco, US.